- The medical cannabis analytics company has developed the first dose-measuring dry herb inhaler
- Its QR code-enabled cartridges allow patients to precisely track their sessions and eliminate the guesswork of finding the right strain
- It uses a robust artificial intelligence platform that aggregates and correlates HIPAA-compliant medical data
What Ryah Medtech does:
Ryah Medtech wants to make sense of the complex medical cannabis industry with data aggregation and artificial intelligence. The privately-held subsidary of Potbotics has developed a suite of products aimed at personalizing medical marijuana to the individual patient.
Enter RYAH, the first dose-measuring inhaler. It's a device that allows medical cannabis patients to precisely control dosage and temperature.
RYAH uses cartridges pre-filled with either dry herb or concentrate. Users simply scan the cartridge’s QR code, set their parameters and RYAH tracks exactly how much vapor has been inhaled.
It pairs with an app that prompts users to rate specific cartridges by selecting physical and mental responses and uses that data to eliminate the guesswork of choosing the correct strain or using the eight amount.
RYAH also has a doctor-facing app that allows physicians to better assess how specific cannabis treatments affect patients.
There’s also PotBot, an app that educates people about cannabinoid care and helps them find strains to treat their specific symptoms. Users input their symptoms, and PotBot’s “virtual budtender” algorithm goes to work, scanning a database of peer-reviewed medical literature to recommend specific strains, dosage levels and consumption methods.
How is it doing:
Now that Ryah Medtech has its flagship project, new CEO Gregory Wagner has stepped in with a plan to take the company from conceptual to commercial.
The company has produced 1,200 devices and 100,000 cartridges, which it plans to sell to its partners once it gets approval from Health Canada and the US Food and Drug Adminsitration.
One June 5, Ryah earned Class 1 device approval for its cartridges. Next comes the device itself, which requires a Class 2 filing. That approval, plus a green light from the FDA, Wagner hopes to receive later this year.
The company doesn’t cultivate its own cannabis, so finding the right growers is crucial. To forge those connections, Wagner is embarking on a North American demo tour, showcasing RYAH to growers and medical professionals alike. In fact, the swell of positive feedback was what first made Wagner confident in the RYAH's ultimate success.
“I asked to be a part of this company,” Wagner told Proactive. “I saw the reviews coming in from the demos, and RYAH is a premium product.”
Once on the market, RYAH cartridges will be sold in 10 states. Devices will be available to consumers within a 30 mile radius of any dispensary that carries the cartridges.
The company has also made penetrating markets in Europe and South American a priority. On May 6, it announced the hiring of Vice President of Business Development Michael Hart, whose primary role is establishing the brand overseas.
Though the company is privately held, that is expected to change soon. It has reserved the ticker RYAH with the Canadian Securities Exchange, and while there isn’t a specific date set yet, Wagner told Proactive the company was in the “seventh inning” of preparing to go public.
Longer term, the company plans to list on OTC Markets and ultimately the Nasdaq in 2020.